Potently neutralizing and protective human antibodies against SARS-CoV-2

Journal: Nature

Published: 2020-07-15

DOI: 10.1038/s41586-020-2548-6

Affiliations: 14

Authors: 41

Go to article
Institutions Share
Vanderbilt Vaccine Center (VCC), VU, United States of America (USA) 0.29
John T. Milliken Department of Medicine, WUSTL, United States of America (USA) 0.21
Center for Virology and Vaccine Research, BIDMC, United States of America (USA) 0.10
UNC Department of Epidemiology, United States of America (USA) 0.10
AstraZeneca Gaithersburg, MD, United States of America (USA) 0.10
Department of Pathology, Microbiology, and Immunology, VU, United States of America (USA) 0.06
Department of Pathology and Immunology, WUSTL, United States of America (USA) 0.04
Department of Chemistry, YVU, India 0.04
Division of Pulmonary and Critical Care Medicine, WUSTL, United States of America (USA) 0.02
Department of Pediatrics, VU, United States of America (USA) 0.02
Faculty of Medicine, Leipzig University, Germany 0.01
Department of Molecular Microbiology, WUSTL, United States of America (USA) 0.01
Washington University School of Medicine (WUSM), WUSTL, United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER